Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study

Figure 1

Pharmacokinetic characteristics of tenapanor-M1 following administration of tenapanor. (a, b) Mean plasma concentration of tenapanor-M1 (semi-log plot) following single dose (a) and repeated dose (b). (c–g) and AUC of tenapanor-M1 following 50 mg single dose (c–e) and repeated dose (f, g) administration of tenapanor in Chinese and Caucasian subjects. The five horizontal lines from the bottom to the top of the box with whisker indicate minimum without outliers, Q1, median, Q3, and maximum without outliers. The triangle or circle inside the box represents the mean value. The triangle or circle outside the box represents the potential outliers.

(a)

(b)

(c)

(d)

(e)

(f)

(g)